Keros Therapeutics Files 8-K

Ticker: KROS · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1664710

Keros Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyKeros Therapeutics, Inc. (KROS)
Form Type8-K
Filed DateJun 17, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Keros filed an 8-K, likely routine but check for material updates.

AI Summary

Keros Therapeutics, Inc. filed an 8-K on June 17, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text.

Why It Matters

This filing indicates Keros Therapeutics is providing updates to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate indication of significant negative news.

Key Players & Entities

  • Keros Therapeutics, Inc. (company) — Registrant
  • June 17, 2024 (date) — Date of earliest event reported
  • 001-39264 (company) — SEC File Number
  • 81-1173868 (company) — I.R.S. Employer Identification No.
  • Lexington, Massachusetts (location) — Principal executive offices

FAQ

What specific 'Other Events' are being reported by Keros Therapeutics in this 8-K filing?

The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported.

What is the exact date of the earliest event reported in this 8-K?

The date of the earliest event reported is June 17, 2024.

What is Keros Therapeutics, Inc.'s SEC File Number?

Keros Therapeutics, Inc.'s SEC File Number is 001-39264.

Where are Keros Therapeutics, Inc.'s principal executive offices located?

Keros Therapeutics, Inc.'s principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.

What is the purpose of this Form 8-K filing for Keros Therapeutics, Inc.?

This Form 8-K is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, intended to report 'Other Events' and 'Financial Statements and Exhibits'.

Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-06-17 06:07:19

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto

Filing Documents

01 Other Events

Item 8.01 Other Events. On June 17, 2024, Keros Therapeutics, Inc. (the "Company") issued a press release announcing additional data from its two ongoing Phase 2 clinical trials of elritercept (KER-050), one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes ("MDS") and one in patients with myelofibrosis ("MF"), at the 29th Annual Hybrid Congress of the European Hematology Association ("EHA"), held virtually and in person from June 13 through 16, 2024. In addition, the Company presented preclinical data showing that, in an animal model of MF, a research form of elritercept promoted erythropoiesis, mitigated anemia associated with MF, improved anemia associated with ruxolitinib therapy and improved muscle mass and function. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. During a conference call and webcast scheduled to be held at 8:00 a.m. Eastern time on June 17, 2024, the Company's management will discuss the additional data from its two ongoing Phase 2 clinical trials of elritercept, one in patients with MDS and one in patients with MF, as well as additional updates to the Company's pipeline. A copy of the presentation for the conference call and webcast is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated June 17 , 2024. 99.2 Investor Presentation dated June 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: June 17, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.